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ABSTRACT

ABSTRACT
Background:
Hyper and hypokalemia is acommon ionic imbalance in patient with heart failure. Increased death and
hospital stay is common in patients with HF and chronic kidney disease (CKD) who have hypokalaemia.
The majority of the intracellular cation is potassium which is necessary to retain anormal charge difference
between the intracellular and extracellular spaces. It often happens as acomplication of certain diseases or
drugs. As hyper or hypokalaemia are potentially hazardous and frequent complication in heartfailure patient
it is important to identify patients who are at increased risk for hypo and hyperkalaemia.
Objectives:
The objective of this study was to identify socio-demographic characteristics, etiological factors and risk
factors for hypo/hyperkalaemia in newly diagnosed patients with heart failure.
Methods:
Heart failure patient details wereretrospectivelyidentified from medical records using ICD 10 code I50.22.
Ethical Committee approval was obtained before start of the study. Based on the inclusion and exclusion
criteria patient’s files was reviewed for demographic information, clinical data, laboratory parameters,
medication history and drugs prescribed and was entered in case record forms (CRF). Type, duration,
severity of illness and co morbid conditions of the patientswere alsorecorded. Control group were heart
failure patients with normal potassium levels. Cases were failure patients developing hyper or hypokalaemia
during the treatment. The obtained data wasanalyzed by using SPSS software using Chi square test and
Logistic regression and expressed as odds ratio (OR).
Results:
Totally, Out of 804 patients details collected retrospectively, 512 were males (63.7%) and 292 (36.3%)
patients were females.hypokalaemiagroup had 194 patients, 110 were males (56.7%) and 84 (43.3%)
patients were females. Likewise, in hyperkalaemia, out of 152 patients, 103(67.8%) were males, females
were found to be 49(32.2%). Hyperkalaemia patients having longer duration of hospital stay (8.1±5.5)
comparatively than hypokalaemia (7.9±5.7).Digoxin had an associated odds ratio [OR: 1.417; CI: 0.9982.012] with the development of hypokalaemia. Spironolactone had an associated odds ratio [OR: 2.101; CI:
1.243-3.551] with the development of hyperkalaemia.
Conclusion:
Our finding may help to better identify patients with heart failure most likely to benefit from
carefulmonitoring of serum potassium level. Improved vigilance is needed during start of treatment with
certain classes of drugs and co-morbid illness.

INTRODUCTION
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INTRODUCTION
Heart failure (HF) has been identified mainly as an elderly disease (> 60 years) (1). HF affects more than 37
million adults around the world and is a major cause of hospitalization and death. HF hospitalization is still
prevalent, and co morbidities, including diabetes mellitus and other disease, are becoming more common,
despite improvements in treatment and prognosis. Patients with kidney disease are more likely to have
hyperkalaemia, and the vibrant link between cardiac and kidney dysfunction, with indications of chronic
kidney disease in more than half of HF patients, has been described in cardio renal. Common electrolyte
disorders like hypokalaemia and hyperkalaemia are caused by changes in intake of potassium, excretion, or
transcellular shifts syndrome.Lesser than 3.5mEq/Lof potassium in serum known as hypokalaemia.
Increased death and hospital stay is common in patients with HF and CKD who have hypokalaemia(2).Severe
and life risking hypokalaemia are described at < 2.5 mEq / L

(3)

.Hyperkalaemia has been discovered on

routine lab tests in heart failure patients, often asymptomatic or associated with mild non specific
symptoms(4).
The majority of the intracellular cation is potassium which is necessary to retain a normal charge difference
between the intracellular and extracellular spaces.It often happens as a complication of certain diseases or
drugs.Modern food has reduced the potassium content significantly. Gastro-intestinal hypo-motility or ileus,
muscle weakness and cramping are all clinical reflections of hypokalaemia

(5)

.

Causes of hypokalaemia

includes usage of laxative, digitalis, insulin; diarrhoea and vomiting, hyperthyroidism, diabetic ketoacidosis,
hyper hydration, hypothermia, cystic fibrosis, hypomagnesaemia, stress, exhaustion and ischemia.
hyperkalaemia can cause both potassium homeostasis abnormalities and external aspects such as drugs and
potassium diet, can elevate potassium levels in patients with severe disease states (6).Renal dysfunctions, T2
DM, Drugs (Mineral corticosteroid antagonist &RAASi) are the common causes of hyperkalaemia (7).
Generally, diagnoses of heart disease, renal failure, malnutrition and shock are related to hypokalaemia.It is
also common in hospitalized patients, especially paediatric, patients withfever, and critically ill
patients.High mortality rate found in children in developing nations when diarrhoea and chronic malnutrition
are associated (8).Around 50% of patients have risk of hypokalaemia who were on diuretic therapy (9).Patients
with heart failure have a high incidence of chronic kidney disease that also increases the risk of
hyperkalaemia, particularly RAASi are used (10)
Metabolic acidosis, rhabdomyolysis, cyst formation, leg cramps, ascending paralysis, constipation, ECG
changes (U waves, T wave flattening, ST segment changes), cardiac arrhythmias and respiratory failures are
the common signs and symptoms of hypokalaemia(1). Nausea, muscle pain and cramps, breathing trouble,
chest pain and dizziness, cold sweating, ECG abnormalities (Peaked T waves, less QT interval, prolonged
PR interval) and arrhythmias are common signs and symptoms of hyperkalaemia(12)(29).

2

Complications of Hypokalaemia and Hyperkalaemia:
Hyperkalaemia may result in the multiple organ dysfunction and cardiac arrest which has high mortality rate
in hospital (28). HF patients with CVD on antihypertensive therapy have increased cause for mortality and
hospitalization (20). When it is associated with arrhythmias, risk becomes life threatening

(21)

.

Accordingly its

risk increases in patients with HF and CKD. Un-recognized hypokalaemia leads to iatrogenic death.
Diuretic drug treatment for hypertension or HF usually involves hypokalaemia. Loop diuretics and digoxin
treatment may result in the common and unlikelyside effect known as hypokalaemia (15). Increased death and
hospital stay is common in patients with HF and CKD who have hypokalaemia (16).Once CHF is advanced
enough, the renal function starts to decline to considerableincrease in risk of developing hyperkalaemia.
Patients with this risk include those with potassium excretion that has already beenaffected, such as the older
population and patients with renal disorders and diabetes (13).In advanced CHF patient with diabetes mellitus,
the propensity to develop hyperkalaemia may be even more likely.
Cardio toxicity can first happen and needs to be addressed urgently. Additionally, major changes in the
Congestive Heart Failure (CHF)drug regimens which are essential to the effective treatment of CHF often
happen after hyperkalaemia (15). In elderly diabetic patients and those who receive drugs that block rennin and
angiotensin II production or action, aldosterone production is reduced. Thus, these groups are particularly
susceptible to the development of hyperkalaemia, due to potassium excretion that is already impaired as a
result of age or disease - related decreases of glomerular filtration rate(16).
Hence, potassium levels need to be supervised in all patients with new diagnoses of hypertension, heart
failure, or any disease that requires RAAS treatment with a diuretic or agents like beta - blockers,
angiotensininhibitors, blockers of angiotensin receptors, inhibitors of vasopeptidase, or a number of K+sparing agents(14)

3

LITERATURE
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LITERATURE REVIEW
Larisa H. Cavallari et al conducted a prospective cohort study with the objective of determining patient
related factors for the elevation of potassium induced by spironolactone in heart failure patients. In this
study they found that increase in the potassium levels (0.5meq/L) when compared with characteristics of
patients, laboratory values and genotypes with those of less potassium elevations followed by the initiation
of
spironolactone,dosetitration.In patients with heart failure who have evidence of high levels of aldosterone, s
uch as high diuretic requirements, the results of the study
suggests that potassium should be monitored with particularattention (18)
An observational study of associations of serum potassium level mortality amongchronic heart failure
patients was carried out by MetteAldahl et al fromDanish National Registries (Denmark).In this study, after
90 days of initiation of loop diuretics, ACEi or ARBs potassium levels were measured and all cause for
mortality were checked and examined.This study showed detailed levels of 3.5–4.1 mmol / L and 4.8–5.0
mmol / L in both lower and upper levels in the normal range for serum potassium, with a significant increase
in the long term risk of mortality in patients with chronic heart failure. In addition, potassium was associated
with increased mortality below 3.5 mmol / L and above 5.0 mmol / L (19)
Núñez J et al conducted a prospective and successive cohort studies on long - term monitoring of potassium
and dynamics of heart failure and mortality risk. In this serum potassiumlevels were evaluated at every
doctor - patient meeting, including in the hospital and outpatient environment. They assessed the
multivariable-adjustment association of serum potassium to mortality. This study details serum potassium
levels independently associated with mortality in patients with heart failure during long-term monitoring. In
comparison with patients maintained or returned to normal values, the continuity of abnormal potassium
levels was also associated with a higher risk of death (27)
HeerspinkHJ et al performed anONTARGET study by which they assumed that hyper and hypokalaemia
both factors are linked to poorer cardiovascular and renal outcomes. With the alone treatment of telmisartan
and dual therapy of RAAS blockade with ACEi, did not reduce the risks and found elevation in the
potassium levels.The association was independent of age, sex and diabetes, estimated filtration rate for
glomerular disease, systemic blood pressure and diuretic treatment. Rare events occurred in hypokalaemia
and hyperkalaemia. Both the high and low serum potassium was nevertheless associated with an increased
risk of diseases related to cardiovascular and renal (26).

Saito M et al retro viewedthe increase in the potassium levels during concomitant therapy of spironolactone
and furosemide with ACEi or ARBs to the chronic heart failure patients for the period of 1 year. They
concluded that dose influences the risk of hyperkalaemia in patients with spironolactone therapy. Also it
5

increases the risk of hyperkalaemia when multiple drug therapy is involved. Hence, always essential to
monitor serum potassium levels (22).
Weir MR et al conducted a study to assess the effects of RAAS inhibitors on serum potassium levels.
Clinical trials published until December 2008were examinedand consisted ofapproximately 39 trials. The
incidence of hyperkalaemiawas low with RAAS inhibitor mono-therapy. The risk of hyperkalaemia with
RAASinhibitors is higher for patients with HF or CKD, compared with patients without these conditions.
The absolute changes in serum potassium, however, are generally small and clinically unlikely. In addition,
the benefit of RAAS inhibition is likely to come from these patients with the conclusion of electrolyte levels
in these patients should be closely monitored instead of denying them effective treatment (23).

The association of potassium and enzymatic up titration inhibitors of angiotensin (ACEi)/angiotensin
receptor blockers (ARB) with its outcome was investigated in BeusekampJC et al. Heart failure has a
common usual co-morbidity of hyperkalaemia with reducedejection fraction. The impact of above factor is
not known with the therapy of RAASi. Higher level of potassium solely suggests the use of ACEi/ARB with
the lower dosages and do not affect the benefit of up titration of the same (24).

6
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NEED FOR THE STUDY
The normal range for serum potassium is3.5 and 5.4 (mEq / L) per litre

(19)

.Changes

in the intake of

potassium, altered excretion and transcellular shifts and use of medication (diuretics, etc.) may cause
hypokalaemiaor hyperkalaemia. Potassium abnormalities can lead to cardiac and neuromuscular dysfunction
and may be life threatening. Numerous studies have demonstrated a U-shaped relationship to both
hypo/hyperkalaemia mortality risks (25).Identifying risk factors that contribute to hyper- and hypokalaemia
will therefore help doctors to evaluate the risk of cardiac failure more effectively. In addition, this research
will contribute to improving patient quality of life and treatment (4).
As hyper or hypokalaemia are potentially hazardous and frequent complication in heartfailure patient it is
important to identify patients who are at increased risk for hypo and hyperkalaemia.Hence study on patients
with hyperkalaemia and hypokalaemia among heart failure patients in our population helps to find the
variant risk factors and improves to help drug therapy and quality of life.

8
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Aim:
To identify the risk factors associated with potassium level abnormalities in Heart failure patients.

Objectives:
To evaluate the potassium status along with risk factors in heart failure patients.

Specific objective:
•

To know the socio-demographic characteristics of hypokalaemia and hyperkalaemia in heart failure
patients.

•

Identification of the etiological factors associated with hypokalaemia / hyperkalaemia in heart failure
patients.

•

To know the past and present medication history of hypo/hyperkalaemia patients with heart failure.

•

To identify the risk factors associated with hyper and hypokalemia in patients with heart failure
using multiple logistic regression.

10

METHODOLOGY
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METHODOLOGY
Study Site: Kasturba Hospital, Manipal.
Study design:Case-control study.
Study period: August 2018 to March 2019
Ethical Approval:
The protocol for this study was approved by the Institutional Ethical Committee of Kasturba Hospital,
MAHE,Manipal. (IEC: 467/2018) dated 15th August 2018 (Appendix 1).
Sample Size: 1035 Patients.

Total
(1035patients)

CASES

CONTROLS

(346 patients)

(458 patients)

Hypokalaemia

Hyperkalaemia

(194 patients)

(152 patients)

MISSING/EXCLUDED
(231 patient files)

Figure 1: Schemattic representation of study population selection.
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Study criteria:
•

Hypokalaemia cases: Heart failure patients with serum potassium levels < 3.6 mEq/L

•

Hyperkalaemia cases: Heart failure patients with serum potassium levels > 5.2 mEq/L

•

Controls: Heart failure patients with serum potassium levels between 3.6 – 5.2 mEq/L

Inclusion criteria:
•

All heart failure patients with serum potassium levels of <3.6 mEq/L and >5.2 mEq/L

•

Patients admitted under cardiology during 2013 -2017

Exclusion criteria:
•

The patients whose serum potassium levels were not checked.

•

Lost patient files

Data source:
Patient Case Records, online clinical laboratory reports.

Study materials
 Case report form (CRF). ( Appendix 2)consists of(demographics, clinical information, lab
parameters, history of medicine, prescribed medicines, type, duration, severity and co - morbidity,
patient conditions).

Operation modality

 Heart failure patient details were retrospectively identified over a 5 years period (Jan 20132017)from MRD files using ICD 10 code I50.22.Ethical Committee approval was obtained prior to
start of the study.
 Control group includedheart failure patients with normal potassium levels. Cases includedheart
failure patients developing hyper or hypokalaemia during the treatment.
 Based on the inclusion and exclusion criteria patient’s files was reviewed for demographic
information, clinical data, laboratory parameters, medication history and drugs prescribed and was
entered in case record forms (CRF). Type, duration, severity of illness and co morbid conditions of
the patientswere collected and recorded in the CRF.

13

Data Analysis
Continuous

data

was

expressed

Mean

+

SD.Nominal

data

expressed

in

frequency

and

percentage.Association between risk factors with hyper/hypokalaemiawas assessed by Chi square test and
Logistic regression and expressed as odds ratio (OR).All statistical analysis were carried out using SPSS
software version 20.0

14
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RESULTS
Results: Among the cohort of 1035 patients with the incident of heart failure, 346 cases were identified. 194
cases of hypokalaemia and 152 cases of hyperkalaemia based on serum potassium levels. 231 files were not
considered either due to non-availability of potassium levels and lost records.Characteristics of demographic
and life style of cases (hypo/ hyperkalaemia) are represented in table 1. Males were 512 (63.7%) and 292
(36.3%) patients were females.Hypokalaemia was present in 110 (56.7%) males and 84 (43.3%) females
(n=194). Hyperkalaemia was present in 103(67.8%) males and 49 (32.2%) females (n=152). The control
group consisted of 458 patients. 364 (45.3 %) patients were found in 31-60 age category and 369 (45.9 %)
of patients are found in 61 - 90 age category. These were the 2 age categories of patients found in large
numbers. The average age of the Heart failure patients was found to be57.2 ± 17.8 years.
Demographic characteristics of Heart failure patients:

Parameter

Total
(n =804 )

57.2±17.8

Age (Mean±SD)

Cases
(n =346 )
Hypokalaemia
(n = 194 )

Hyperkalaemia
(n= 152 )

Control
(n = 458)
Normal
K+levels

56.3±20.7

56.8±17.7

8.0±5.7

8.1±5.5

6.3±4.1

58.7±15.6

Length of hospital stay
7.0±4.9

(Mean±SD)
Age category
•

≤5, n (%)

26(3.2%)

2(1%)

8(5.3%)

16(3.5%)

•

6-10, n (%)

2(0.2%)

----

1(0.7%)

1(0.2%)

•

11-30, n (%)

38(4.7%)

10(5.2%)

10(6.6%)

18(3.9%)

•

31-60, n (%)

364(45.3%)

93(47.9%)

54(35.5%)

217(47.4%)

•

61-90, n (%)

369(45.9%)

89(45.9%)

77(50.7%)

203(44.3%)

•

≥91, n (%)

5(0.6%)

----

2(1.3%)

• Males, n (%)

512(63.7%)

110(56.7%)

103(67.8%)

• Females, n (%)

292(36.3%)

84(43.3%)

49(32.2%)

3(0.7%)

Gender, n (%)
299(65.3%)
159(34.7%)

16

4(2.6%)

7(1.5%)

5(2.6%)

8(5.3%)

13(2.8%)

6(0.7%)

2(1%)

1(0.7%)

3(0.7%)

16(2%)

1(0.5%)

6(3.9%)

9(2%)

2(1%)

5(3.3%)

3(0.7%)

Smoking, n (%)

13(1.6%)

Alcoholism, n (%)

26(3.2%)

Tobacco chewer, n (%)
Smoker +Alcoholic, n (%)
Reformed smoker + alcoholic, n(%)

10(1.2%)

Tobacco chewer + alcoholic, n (%)

2(0.2%)

2(1%)

1(0.5%)

----

1(0.2%)

Mortality, n (%)
•

Alive

742(92.3%)

•

Dead

62(7.7%)

176(90.7%)
18(9.3%)

137(90.1%)

429(93.7%)

15(9.9%)

29(6.3%)

Table 1: Demographic and life style characteristics of patients of case (hypo/hyperkalaemia) and
control
Gender wise distribution of Heart failure patients:
A total of 804 patients details were collected retrospectively out of 1035 patients. Males were 512 (63.7%)
and 292 (36.3%) patients were females.Hypokalaemia was present in 110 (56.7%) males and 84 (43.3%)
females (n=194). Hyperkalaemia was present in 103(67.8%) males and 49 (32.2%) females (n=152).
Age group wise distribution of Heart failure patients:
Around 364 (45.3 %) patients found in 31-60 age category and 61 - 90 elderly patients found in 369 (45.9
%), which were the two categories of patients that found a large number of patients. The average age of the
Heart failure patients was found to be57.2±17.8 years.
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Distribution of Heart failure patients based on hyperkalaemia and hypokalaemia:

n (%)

24%
Hypokalemia
Hyperkalemia
Normal potassium levels

57%
19%

Figure 2. Distribution of heart failure patients based on hyperkalaemia and hypokalaemia.

Out of 804 patients, 458 (57%) patients had Normal level of potassium, 194 (24.1%) patients diagnosed with
hypokalaemia. Similarly, 152(18.9%) patients had hyperkalaemia. In this, Hyperkalaemia and hypokalaemia
kept under Case group and Normal potassium level patients under control groups.
Mortality:
In the total sample size of 804 out of 1035 patients which were collected retrospectively, 742(92.3%)
patients were Alive and 62(7.7%) were found to be dead. In hypokalaemia, 176(90.7%) patients found Alive
along with 18(9.3%) dead patients. Hyperkalaemia patients included 137(9.1%) alive and 15(9.9%) dead
patients.429(93.7%) Alive patients and 29(6.3%) dead patients were found in Control group patients who
were having Normal potassium levels.
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Medical History:
Patients having both hypertension and diabetes mellitus were higher in the group developing hyperkalaemia.
However, patients having only hypertension were higher in the hypokalemic group
(Table 2).
Disease

Total
(n = 804)
n (%)

Cases
(n= 346)
Hypokalaemia,
n= (194)

Control
(n = 458)
Hyperkalaemia,
n= (152)

Hypertension

73(9.1%)

28(14.4%)

7(4.6%)

38(8.3%)

IHD

41(5.1%)

7(3.6%)

6(3.9%)

28(6.1%)

T2 DM

77(9.6%)

18(9.3%)

16(10.5%)

18(9.3%)

RHD

18(2.2%)

4(2.1%)

3(2%)

11(2.4%)

HTN+Dm

106(13.2%)

25(12.9%)

30(19.7%)

52(11.4%)

COPD+IHD

11(1.4%)

-----

2(1.3%)

9(2%)

DM+HTN+BA+TB

11(1.4%)

3(1.5%)

2(1.3%)

IHD+HTN

21(2.6%)

5(2.6%)

2(1.3%)

14(3.1%)

IHD+T2DM+HTN

37(4.6%)

5(2.6%)

5(3.3%)

27(5.9%)

Dm+IHD

18(2.2%)

5(2.6%)

2(1.3%)

11(2.4%)

IHD+T2DM+CKD+HTN

25(3.1%)

3(1.5%)

7(4.6%)

15(3.3%)

Others

100(12.4%)

23(11.8%)

24(15.9%)

52(11.2%)

None

266(33.1%)

68(35.1%)

46(30.3%)

152(33.2%)

6(1.3%)

Table2: Co-morbities in study population
Medication history:
The descriptive analysis of past medications revealed higher usage of anti-diabetic drugs among
hyperkalaemia 10(6.6%) compared to hypokalaemia 6(3.1%) patients. In control group patients the usage of
anti-diabetic drugs found to be 17(3.7%). Others drugs included are beta blockers, ARBs, nitrates, antiarrhythmic drugs, warfare, CCb+ARBs, ARBs+Nitrates+ACEi+Diuretics+Aspirin, Antiarrythmicdrugs+Aspirin+Lipidloweringagent+Antidiabetic+Thyroid agent. (Table 3).
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Medications

Total
(n = 804)
n (%)

Cases
(n = 346)
Hypokalaemia,

Hyperkalaemia,
n= (152)

n= (194)
Antidiabetics
33(4.1%)
Antibiotics
6(0.7%)
Antihypertensive
5(0.6%)
Diuretics
4(0.5%)
CCB
9(1.1%)
Digoxin
3(0.4%)
Aspirin
9(1.1%)
CCB+ Diuretics+
10(1.2%)
Aspirinatorvastatin+
Antidiabetic
Diuretics+ CCB
15(1.9%)
Antidiabetic+ Diuretics
13
Aspirin+Antidiabetics+ CCB
13(1.6%)
Others
18(2.4%)
None
662(82.3%)
Table3 : Past medication history in study population.

Control
(n = 458)

6(3.1%)
3(1.5%)
1(0.5%)
1(0.5%)
1(0.5%)
1(0.5%)
--3(1.5%)

10(6.6%)
1(0.7%)
1(0.7%)
---2(1.3%)
---2(1.3%)
4(2.6%)

17(3.7%)
2(0.4%)
3(0.7%)
3(0.7%)
6(1.3%)
2(0.4%)
7(1.5%)
3(0.7%)

3(1.5%)
4(2.1%)
1(0.5%)
8(4.3%)
162(83.5%)

2(1.3%)
4(2.6%)
2(1.3%)
6(4.1%)
118(77.6%)

10(2.2%)
9(2%)
10(2.2%)
2(0.4%)
382(83.4%)

Multivariate analysis:
A criteria of p<0.05 at 95% CI was selected and variables exhibiting the significance criteria and adequate
sample size were further evaluated using multiple logistic regression. Digoxin had an associated odds ratio
[OR: 1.417; CI: 0.998-2.012] with the development of hypokalaemia. However, Combination of
Aspirin/acetylsalicylicacid+Atorvastatin+Clopidogrel was found to be protective [OR: 0.407; CI: 0.1900.872] to the development of hypokalaemia (Table4).
Factors
Alpha and Beta blocker
Digoxin
Aspirin/acetylsalicylicacid+
Atorvastatin+Clopidogrel
Torasemide

Odds ratio

95%CI

P value

1.853
1.417

0.936- 3.669
0.998-2.012

0.08
0.05

0.407
1.425

0.190-0.872
0.944–2.151

0.02
0.92

Table4: Association of risk factors (drugs) with hypokalaemia.
Spironolactone had an associated odds ratio [OR: 2.101; CI: 1.243-3.551] with the development of
hyperkalaemia (Table 5).
Factors
Spironolactone
Furosemide + Spironolactone
UFH

Odds ratio
2.101
1.790
0.609

95%CI
1.243- 3.551
0.161-2.760
0.368-1.009

P value
0.01
0.05
0.05

Table 5: Association of risk factors (drugs) with hyperkalaemia.
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DISCUSSION
Heart failure is a clinical condition resulting in a low standard of living, high morbidity and high mortality.
Co - morbidities often lead to heart failure and aggravate the decline in standard of life and clinical results.
The patho-physiological processes underlying the interactivity of heart failure with co - morbid conditions
are complex (21).
In this study, Male preponderance (512, 63.7%)was observed. There appears to be more male patients (369,
45.9%)in the 61 - 90 age category. Evidently, the hyperkalaemiagroup observed more patients with both
diabetes mellitus and hypertension (30, 19.7%).This study reported, hyperkalaemia patientshadlonger
duration of hospital stay(8.1±5.5 days)comparatively than hypokalaemia(8.0±5.7 days).Relatively, mortality
rate was found higher in hyperkalaemia(15, 9.9%) group. Hence, the descriptive analysis of past medicines
revealed that patients with hyperkalaemia (10, 6.6%) had higher anti-diabetic drug usage compared to
patients with hypokalaemia (6, 3.1%).Similar results were observed in the study by Desai as et al. wherein,
male gender ≥75 years were more prone to developing hyperkalaemia (28).The result was corroborated in a
study by Jain N et al wherein, prolonged stay in hospital and the higher mortality rate were observed
with cardio-vascular diseases(hypertension and heart failure) and DM (20).
In this study, Digoxin was found to be a risk factor with an odds ratio [OR: 1.417; CI: 0.998-2.012] which
resulted in significant development of hypokalaemia. An article published by Bielecka-Dabrowa A details
about, hypokalaemia which has become a common and despised residual effect with digoxin
therapy,explaining enhanced neuro-hormonal activity or progression of the disease could also be highlighted
with the low K(+) serum of HF(17).
In this analysis, Spironolactone was found to be a risk factor for hyperkalaemia with an odds ratio [OR:
2.101; CI: 1.243-3.551].The study by Desai AS et al showed increasedrisk of hyperkalaemia with
spironolactone therapy. Progressing age, male gender, renal insufficiency, diabetes, or combined RAAS
obstruction increases the occurrence of hyperkalaemia (28). Similarly, an article by Viayakumar S et al also
reported a particularly increased risk of chronic or recurrent hyperkalaemia in patients withreninangiotensin-aldosterone system inhibitors (RAASi).The study also examines barriers to guideline - mediated
RAASi patterns in patients posing high riskof hyperkalaemia (6).
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LIMITATIONS
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LIMITATIONS
•

As this study was single center retrospective study , availability of the sufficient data were less

•

Assessing patient medication adherence was not possible in the medication history as the study was
retrospective in nature. Hence, this was not taken into consideration.
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CONCLUSION

25

CONCLUSION
Our finding may help to better identify patients with heart failure most likely to benefit from
carefulmonitoring of serum potassium level. Improved vigilance is needed during start of treatment with
certainclasses of drugs and co-morbid illness.
.
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FUTURE DIRECTIONS
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FUTURE DIRECTIONS:
•

Large duration studies with more sample size studies may give proper and appropriate results
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